CLINICAL_TRIALS
trial_result
· 2017-06-06
Clinical Trial Update: Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer [Phase 2]
Summary
Phase 2 trial of ADI-PEG 20 in relapsed sensitive or refractory small cell lung cancer was terminated; results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ludwig Institute for Cancer Research | Conditions: Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-06-06